Table 3.
Preclinical model | G. biloba (concentration or dose) | Effect(s) | Reference(s) |
---|---|---|---|
Myoblasts | 25–100 µg/mL | Cytoprotection from alcohol-induced oxidative damage | (Wang et al., 2015) |
Endothelial cells | 50–200 µg/mL | Endothelial protection from high-glucose- or TNF-α–induced vascular oxidative damage; cytoprotection against cigarette smoke-induced apoptosis in lungs | (Hsu et al., 2009; Chen et al., 2011; Tsai et al., 2013) |
Macrophages | 1–100 µg/mL | Inhibition of inflammatory damage in LPS-treated cells; regulation of cholesterol homeostasis and reduction in atherosclerosis lesion size | (Tsai et al., 2010; Ryu et al., 2012) |
Ethanol-induced liver damage in rats | 48 or 96 mg/kg intragastric for 90 days | Reduction of oxidative damage and improvement of ethanol-induced microvesicular steatosis and parenchimatous degeneration in hepatocytes | (Yao et al., 2007) |
LPS, lipopolysaccharide; TNF, tumor necrosis factor.